Ontology highlight
ABSTRACT:
SUBMITTER: Stevens AM
PROVIDER: S-EPMC6929386 | biostudies-literature | 2019 Dec
REPOSITORIES: biostudies-literature
Stevens Alexandra M AM Xiang Michael M Heppler Lisa N LN Tošić Isidora I Jiang Kevin K Munoz Jaime O JO Gaikwad Amos S AS Horton Terzah M TM Long Xin X Narayanan Padmini P Seashore Elizabeth L EL Terrell Maci C MC Rashid Raushan R Krueger Michael J MJ Mangubat-Medina Alicia E AE Ball Zachary T ZT Sumazin Pavel P Walker Sarah R SR Hamada Yoshimasa Y Oyadomari Seiichi S Redell Michele S MS Frank David A DA
Blood advances 20191201 24
Atovaquone, a US Food and Drug Administration-approved antiparasitic drug previously shown to reduce interleukin-6/STAT3 signaling in myeloma cells, is well tolerated, and plasma concentrations of 40 to 80 µM have been achieved with pediatric and adult dosing. We conducted preclinical testing of atovaquone with acute myeloid leukemia (AML) cell lines and pediatric patient samples. Atovaquone induced apoptosis with an EC50 <30 µM for most AML lines and primary pediatric AML specimens. In NSG mice ...[more]